SAB Biotherapeutics Swings to Q3 Net Loss of $22.3 Million

PUBT · 5d ago
SAB Biotherapeutics Swings to Q3 Net Loss of $22.3 Million
  • SAB Biotherapeutics swung to a Q3 2026 net loss of $22.3 million from year-earlier net income of $45.4 million.
  • Research and development expenses more than doubled to $18.1 million; general and administrative expenses more than doubled to $7.8 million.
  • Cash, cash equivalents and investment securities totaled $205.3 million at September 30, providing operational runway through 2028.
  • SAFEGUARD enrollment remains on track for completion in Q4 2026, with topline data expected in the second half of 2027.
  • SAB-142 received FDA Fast Track designation in October 2026 for treatment of new-onset Stage 3 type 1 diabetes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870502) on November 05, 2026, and is solely responsible for the information contained therein.